Literature DB >> 17582578

Pharmacokinetics and pharmacodynamics of antimicrobials.

G L Drusano1.   

Abstract

Antibiotics are some of our most commonly used drugs. Until recently, little has been known about how to optimize administration of these agents. Unfortunately, the rate of discovery of new antibiotics has been declining, coincident with the explosion in the number of multidrug-resistant organisms in both the community and hospital environments. This development makes the identification of optimal regimens that will result in good clinical and microbiological outcomes important, but it also makes clear the necessity of identifying regimens that will suppress the emergence of resistant organisms. Given that new agents for multidrug-resistant pathogens will take nearly a decade to become available to physicians, keeping organisms susceptible to drugs that are already available is even more critical. Pharmacodynamics allows identification of the drug exposure measure that is closely associated with the ability to kill organisms and, also, to suppress the emergence of resistant subpopulations of organisms. Use of Monte Carlo simulation allows identification of drug doses in the clinical arena to accomplish these ends. Such approaches should be applied to all old and new antibacterial agents.

Mesh:

Substances:

Year:  2007        PMID: 17582578     DOI: 10.1086/518137

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  52 in total

1.  Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.

Authors:  Bruce R Levin; Klas I Udekwu
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

Review 2.  Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

Authors:  Lizanne Béïque; Rosemary Zvonar
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

3.  Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections?

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Susceptible, intermediate, and resistant - the intensity of antibiotic action.

Authors:  Arne Rodloff; Torsten Bauer; Santiago Ewig; Peter Kujath; Eckhard Müller
Journal:  Dtsch Arztebl Int       Date:  2008-09-26       Impact factor: 5.594

Review 5.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Authors:  Thomas P Lodise; Mark Gotfried; Steven Barriere; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

7.  Piperacillin-tazobactam penetration into human pancreatic juice.

Authors:  Elisa Bertazzoni Minelli; Anna Benini; Luigina Franco; Claudio Bassi; Paolo Pederzoli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

8.  In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

Authors:  Yuan-Cheng Chen; Wang Liang; Jia-Li Hu; Gao-Li He; Xiao-Jie Wu; Xiao-Fang Liu; Jing Zhang; Xue-Qian Hu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-30       Impact factor: 2.745

Review 9.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

10.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.